Crossmark

Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion–positive non-small cell lung cancer in the United States

Crossref DOI link: https://doi.org/10.1007/s11096-024-01800-3

Published Online: 2024-10-01

Published Print: 2024-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yi, Hongbin https://orcid.org/0000-0003-2602-3959
Cao, Yingdan https://orcid.org/0009-0006-7414-4674
Shi, Fenghao https://orcid.org/0009-0008-2876-7920
Wei, Xiaoxia https://orcid.org/0000-0003-2443-1203
Han, Sheng https://orcid.org/0000-0001-5975-3574
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-01
More Information

Article History

Received: 29 April 2024

Accepted: 26 August 2024

First Online: 1 October 2024

Conflicts of interest

: All of the authors have indicated that they have no conflicts of interest with regard to the content of the article. This manuscript is original and has not been previously published, nor has it been simultaneously submitted to any other journal.

Document is current

Any future updates will be listed below